175 related articles for article (PubMed ID: 20576385)
21. Impact of whole-body imaging on treatment decision to radio-frequency ablation in patients with malignant liver tumors: comparison of [18F]fluorodeoxyglucose-PET/computed tomography, PET and computed tomography.
Kuehl H; Rosenbaum-Krumme S; Veit-Haibach P; Stergar H; Forsting M; Bockisch A; Antoch G
Nucl Med Commun; 2008 Jul; 29(7):599-606. PubMed ID: 18528181
[TBL] [Abstract][Full Text] [Related]
22. The Role of 18F-FDG PET/CT in the evaluation of Ascites of Undetermined Origin.
Zhang M; Jiang X; Zhang M; Xu H; Zhai G; Li B
J Nucl Med; 2009 Apr; 50(4):506-12. PubMed ID: 19289438
[TBL] [Abstract][Full Text] [Related]
23. Positron emission tomography/computed tomography with 18fluoro-deoxyglucose in the detection of local recurrence and distant metastases of pediatric sarcoma.
Arush MW; Israel O; Postovsky S; Militianu D; Meller I; Zaidman I; Sapir AE; Bar-Shalom R
Pediatr Blood Cancer; 2007 Dec; 49(7):901-5. PubMed ID: 17252575
[TBL] [Abstract][Full Text] [Related]
24. Clinical role of 18F-FDG PET/CT in the management of squamous cell carcinoma of the head and neck and thyroid carcinoma.
Quon A; Fischbein NJ; McDougall IR; Le QT; Loo BW; Pinto H; Kaplan MJ
J Nucl Med; 2007 Jan; 48 Suppl 1():58S-67S. PubMed ID: 17204721
[TBL] [Abstract][Full Text] [Related]
25. 18F-FDG PET/CT delayed images after diuretic for restaging invasive bladder cancer.
Anjos DA; Etchebehere EC; Ramos CD; Santos AO; Albertotti C; Camargo EE
J Nucl Med; 2007 May; 48(5):764-70. PubMed ID: 17475965
[TBL] [Abstract][Full Text] [Related]
26. Integrated contrast-enhanced diagnostic whole-body PET/CT as a first-line restaging modality in patients with suspected metastatic recurrence of breast cancer.
Dirisamer A; Halpern BS; Flöry D; Wolf F; Beheshti M; Mayerhoefer ME; Langsteger W
Eur J Radiol; 2010 Feb; 73(2):294-9. PubMed ID: 19181468
[TBL] [Abstract][Full Text] [Related]
27. Pediatric FDG PET/CT: physiologic uptake, normal variants, and benign conditions.
Shammas A; Lim R; Charron M
Radiographics; 2009; 29(5):1467-86. PubMed ID: 19755606
[TBL] [Abstract][Full Text] [Related]
28. (18)F-FDG-PET/CT in evaluating response to therapy in solid tumors: where we are and where we can go.
Herrmann K; Benz MR; Krause BJ; Pomykala KL; Buck AK; Czernin J
Q J Nucl Med Mol Imaging; 2011 Dec; 55(6):620-32. PubMed ID: 22231582
[TBL] [Abstract][Full Text] [Related]
29. 18F-FDG PET and 18F-FDG PET/CT for assessing response to therapy in esophageal cancer.
Krause BJ; Herrmann K; Wieder H; zum Büschenfelde CM
J Nucl Med; 2009 May; 50 Suppl 1():89S-96S. PubMed ID: 19380406
[TBL] [Abstract][Full Text] [Related]
30. Integrating PET and PET/CT into the risk-adapted therapy of lymphoma.
Kasamon YL; Jones RJ; Wahl RL
J Nucl Med; 2007 Jan; 48 Suppl 1():19S-27S. PubMed ID: 17204717
[TBL] [Abstract][Full Text] [Related]
31. F-18 FDG PET/CT evaluation of osseous and soft tissue sarcomas.
Iagaru A; Quon A; McDougall IR; Gambhir SS
Clin Nucl Med; 2006 Dec; 31(12):754-60. PubMed ID: 17117068
[TBL] [Abstract][Full Text] [Related]
32. Optimized contrast-enhanced CT protocols for diagnostic whole-body 18F-FDG PET/CT: technical aspects of single-phase versus multiphase CT imaging.
Brechtel K; Klein M; Vogel M; Mueller M; Aschoff P; Beyer T; Eschmann SM; Bares R; Claussen CD; Pfannenberg AC
J Nucl Med; 2006 Mar; 47(3):470-6. PubMed ID: 16513616
[TBL] [Abstract][Full Text] [Related]
33. Impact of FDG PET/CT on delineation of the gross tumor volume for radiation planning in non-small-cell lung cancer.
Spratt DE; Diaz R; McElmurray J; Csiki I; Duggan D; Lu B; Delbeke D
Clin Nucl Med; 2010 Apr; 35(4):237-43. PubMed ID: 20305410
[TBL] [Abstract][Full Text] [Related]
34. Assessing tumor response to therapy.
Weber WA
J Nucl Med; 2009 May; 50 Suppl 1():1S-10S. PubMed ID: 19380403
[TBL] [Abstract][Full Text] [Related]
35. Scanning with 18F-FDG-PET/CT for detection of pelvic nodal involvement in inguinal node-positive penile carcinoma.
Graafland NM; Leijte JA; Valdés Olmos RA; Hoefnagel CA; Teertstra HJ; Horenblas S
Eur Urol; 2009 Aug; 56(2):339-45. PubMed ID: 19477581
[TBL] [Abstract][Full Text] [Related]
36. PET/CT in pediatric oncology.
Samuel AM
Indian J Cancer; 2010; 47(4):360-70. PubMed ID: 21131747
[TBL] [Abstract][Full Text] [Related]
37. [Whole-body MRI and FDG-PET/CT imaging diagnostics in oncology].
Schmidt GP; Haug A; Reiser MF; Rist C
Radiologe; 2010 Apr; 50(4):329-38. PubMed ID: 20229091
[TBL] [Abstract][Full Text] [Related]
38. [Combined functional and morphological imaging of sarcomas: significance for diagnostics and therapy monitoring].
Schramm N; Schlemmer M; Rist C; Issels R; Reiser MF; Berger F
Radiologe; 2010 Apr; 50(4):339-48. PubMed ID: 20221579
[TBL] [Abstract][Full Text] [Related]
39. Whole-body PET/CT studies with lowered ¹⁸F-FDG doses: the influence of body mass index in dose reduction.
Sánchez-Jurado R; Devis M; Sanz R; Aguilar JE; del Puig Cózar M; Ferrer-Rebolleda J
J Nucl Med Technol; 2014 Mar; 42(1):62-7. PubMed ID: 24503348
[TBL] [Abstract][Full Text] [Related]
40. Whole-body 18F-FDG PET/CT: the need for a standardized field of view--a referring-physician aid.
Huston SF; Abdelmalik AG; Nguyen NC; Farghaly HR; Osman MM
J Nucl Med Technol; 2010 Sep; 38(3):123-7. PubMed ID: 20724533
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
